Study objective: Tto evaluate influence of moxonidine therapy on carotid wall thickness, heart structural and functional parametres in hypertensive postmenopausal women with metabolic syndrome (MS).
Material and methods: 56 hypertensive (AH grades 1-2) postmenopausal women with metabolic syndrome 45-55 years old (52,5+/-0,4 years). MS was diagnosed according to ESC-ESH (2007) criteria. Patients were treated with moxonidine (200-600 mcg/day) orally. Structure and function of the heart and the intima-media thickness of carotid arteries were reviewed by ultrasound method before therapy and on 12-th week of treatment with moxonidine. Statistical analyses were performed using SPSS 20.0 for Windows.
Results:b> 55,8%hypertensive postmenopausal women with MS had elevated left ventricle mass index (LVMI more than 110 g/m2). 34,6% patients had LV diastolic dysfunction. We revealed correlation between LVMI, interventricular septum thickness, E/A ratio and systolic BP (r=0,4; 0,4 and -0,4, accordingly; p=0,02; 0,04 and 0,02 accordingly). Positive correlation was revealed between interventricular septum thickness and diastolic BP (r=0,4; p=0,07); left atrium diameter and diastolic BP (r=0,4; p=0,04). Moxonidine therapy did not changed intima-media thickness of carotid arteries (0,86+/-0,03 mm vs 0,81+/-0,04 mm; p=0,05) and LVMI (114,0+/-3,4 g/m2 and 113,9+/-3,4 g/m2, p>0,05 ). LV diastolic function improved: E/A ratio increased from 1,05+/- 0,03 to 1,20+/- 0,03 (p< 0,001), and IVRT decreased from 97,3+/-3,0 msec to 91,8+/-3,1 msec (p< 0,001). Number of patients with E/A ratio less than 1,0 decreased from 34,6% to 7,7% women (?< 0,05). Left atrium diameter reduced (4,30+/-0,08 cm and 4,21+/-0,07 cm; p< 0,05), left atrium volume also decreased (29,8+/-0,6 ml/m2 and 29,1+/-0,6 ml/m2; p< 0,05), (picture).
Conclusions: moxonidine therapy improved left ventricle diastolic function and decreased left atrium diameter and left atrium volume in hypertensive postmenopausal women with metabolic syndrome.